CDC pauses COVID vaccine study over methodology concerns, reports say

A Centers for Disease Control and Prevention report that had estimated roughly a 50 percent reduction in emergency‑department and urgent‑care visits and a 55 percent reduction in hospitalizations among healthy adults who received COVID‑19 vaccination during September–December 2025 was removed from the agency’s Morbidity and Mortality Weekly Report publication queue after the acting CDC director raised methodological concerns. The paper had been slated for publication on March 19, 2026; the pause was publicly reported April 9–10, 2026.

The intervention was initiated by Jay Bhattacharya, who was serving as acting CDC director while also holding the post of National Institutes of Health director after his February 18, 2026 appointment to the acting CDC role. HHS spokesman Andrew Nixon said the agency had asked for additional review to ensure the paper used "the most appropriate methodology for such a study." Agency officials described the pause as a targeted review of analytic choices rather than a rejection of the underlying data.

Reporting identified the methodology under scrutiny as a test‑negative design, a commonly used observational approach in influenza and COVID‑19 vaccine‑effectiveness monitoring. In this design, people who seek care for similar symptoms and test positive are compared with those who test negative to estimate vaccine effectiveness. Small analytic choices matter: case definitions, how prior infection is handled, which confounders are adjusted for, how vaccination status is ascertained, and the specific Sept–Dec 2025 time window can materially change point estimates and confidence intervals.

The review has prompted concern among career public‑health scientists and former agency officials about editorial norms at MMWR. Former CDC chief medical officer Debra Houry observed that a political appointee would very rarely be involved in MMWR review and that such reports were "previously ... reviewed by a career scientist who worked across administrations." Some unnamed CDC scientists speaking on background said the draft had passed internal scientific review before the acting director raised questions, and those scientists said they feared retaliation if identified.

The timing matters for policy. If the final report sustains draft estimates of about 50 percent fewer ED visits and 55 percent fewer hospitalizations, it could bolster arguments for broader booster outreach to adults without high‑risk conditions ahead of the next respiratory‑virus season. If methodological corrections widen confidence intervals or alter effect sizes, messaging and booster recommendations could be scaled back or recalibrated. The American Medical Association and partners launched an independent vaccine‑science review in February 2026 amid wider worries about CDC review processes, a background that has amplified calls for transparent documentation of the issues being considered.

CDC said the review will be completed before formal publication; what follows will test both the robustness of the Sept–Dec 2025 estimates and procedural norms at an agency whose MMWR series has been published in its modern form since the 1950s. How HHS and CDC document the methodological questions and the final analytic choices will shape not only vaccine guidance but public confidence in federal scientific reporting out of Atlanta and Washington, D.C.